Nefazodone for Chronic Daily Headache Prophylaxis: An Open‐Label Study

@article{Saper2001NefazodoneFC,
  title={Nefazodone for Chronic Daily Headache Prophylaxis: An Open‐Label Study},
  author={Joel R. Saper and Alvin E. Lake and Stewart J. Tepper},
  journal={Headache: The Journal of Head and Face Pain},
  year={2001},
  volume={41}
}
Objective.—To assess effectiveness, tolerability, and safety of nefazodone as a prophylactic agent for chronic daily headache. 
Predictors of a Negative Response to Topiramate Therapy in Patients With Chronic Migraine
TLDR
To identify variables predictive of a negative response to prophylactic therapy with topiramate in patients with chronic migraine, a large number of patients have suffered from chronic migraine.
Prophylactic migraine therapy: Emerging treatment options
TLDR
Data is presented on topiramate, levetiracetam, zonisamide, botulinim toxin, tizanidine, nefazodone, lisinopril, candesartan, carabersat, petasites, and coenzyme Q.
Preventive migraine therapy: what is new
TLDR
This paper reviews new treatment options for migraine prevention and focuses on new drugs, some of which were acquired in well design double blind, controlled studies, while the efficacy of other medication is supported only by open, uncontrolled trials.
Migraine preventive therapy: current and emerging treatment options
TLDR
This paper starts with an overview about migraine and then briefly discusses current indications for migraine prevention and new and emerging preventive medications.
The pharmacological management of migraine, part 2: preventative therapy.
  • G. Demaagd
  • Medicine
    P & T : a peer-reviewed journal for formulary management
  • 2008
TLDR
The role of preventative (prophylactic) pharmacotherapy and the role of migraine treatments in special populations are discussed and an overview and guideline summary for general treatment pathways for the pharmacotherapy of migraine is provided.
Gabapentin in the prophylaxis of chronic daily headache
TLDR
Gabapentin represents a therapeutic option for chronic daily headache and reduction in headache days/month was seen across the spectrum of prerandomization headache frequencies.
Indicators of a Major Depressive Episode in Primary Care Patients With a Chief Complaint of Headache
TLDR
To identify the indicators of major depressive episode (MDE) in primary care patients with a chief complaint of headache with the aim of identifying those who are at high risk of depression.
Pharmacologic Approaches to CDH: Evidence and Outcomes
TLDR
Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of chronic migraine (CM), and there are other neuromodulators, beta-blockers, calcium channel blockers, or antidepressants useful in the management of this population of patients.
CHRONIC DAILY HEADACHE AND ITS SUBTYPES
TLDR
Effective treatment regimens will be discussed, which include the following steps: education and support to the patient, establishing expectations and a follow-up plan, use of nonpharmacological and behavioral therapies, and discontinuation of overused and potentially offending medications by outpatient or inpatient detoxification procedures.
Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management
TLDR
The scope of this chapter would be to update the knowledge regarding serotonin involving in pain pathways and to highlight the importance and contribution of serotonin reuptake inhibitors in the multimodal pain management schemes.
...
1
2
3
4
...

References

SHOWING 1-10 OF 32 REFERENCES
Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
TLDR
Data suggest that nefazodone is a worthwhile treatment alternative to tricyclic antidepressants and SSRIs in patients with major depression, and has a lower incidence of adverse anticholinergic, antihistaminergic and adrenergic effects.
Nefazodone: Its Place among Antidepressants
TLDR
Nefazodone appears to have a milder adverse effect profile than the tricyclic antidepressants, causes fewer sexual dysfunctions than the serotonin selective reuptake inhibitors, and may cause less dizziness than trazodone.
The safety profile of nefazodone.
Comprehensive review of safety data from approximately 3500 patients who received nefazodone in premarketing clinical trials demonstrates the drug to be very well tolerated, with a favorable side
Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.
TLDR
Nefazodone and sertraline are well tolerated, and there was no statistically significant difference in their antidepressant activity.
Transformed migraine, analgesic rebound, and other chronic daily headaches.
TLDR
There is a need for an expanded and modified classification and broader understanding of chronic headaches, and the author proposes new categories, including transformed migraine.
Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study
TLDR
It is concluded that flunarizine is an effective drug for the treatment of childhood migraine and in a study of this length no serious side effects were discovered.
Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial.
TLDR
Findings indicate that tricyclic antidepressants are of considerable benefit in relatively mild depressions, except in the mildest range.
Nefazodone: a new antidepressant.
  • V. Ellingrod, P. Perry
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1995
TLDR
In placebo-controlled trials, nefazodone was as effective as imipramine for the treatment of major depression and produced clinical benefits in patients with depression-related anxiety and sleep disturbances.
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
TLDR
Differences between treatment groups revealed greater sleep efficiency, fewer awakenings, less percent awake and movement time, more REM sleep, and shorter REM latency for nefazodone compared with fluoxetine.
Antidepressant‐Induced Sexual Dysfunction: Review, Classification, and Suggestions for Treatment
  • J. Ellison
  • Psychology, Medicine
    Harvard review of psychiatry
  • 1998
TLDR
Once an antidepressant‐induced sexual dysfunction is detected and its nature is characterized, an appropriate treatment intervention can be chosen in order to alleviate the sexual disorder and enhance treatment compliance.
...
1
2
3
4
...